FREMONT, Calif., Jan. 24, 2019 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat...
ALAMEDA, Calif., Jan. 04, 2019 (GLOBE NEWSWIRE) -- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced the appointment...
FREMONT, Calif., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cellular immunotherapies to treat cancer...
Clinical Programs Continue to ProgressRecent Transactions with affiliate of Novo Nordisk Increased Cash-on-Hand and Reduced Annual Operating ExpensesRecently Announced Definitive Merger Agreement...
BioTime Acquires Two Clinical-Stage Cell Therapy Product Candidates Addressing Significant Unmet Needs in Spinal Cord Injury and Immuno-Oncology Asterias Stockholders to Receive 0.71...
Industry Veteran Brian M. Culley Appointed as CEO Signed Agreement to Acquire Asterias Biotherapeutics, Inc. Received $43.2 Million from AgeX Sale Transaction with Juvenescence...
FREMONT, Calif., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat...
Meeting with Food and Drug Administration Remains on Track for End of 2018 FREMONT, Calif., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a...
FREMONT, Calif., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat...
FREMONT, Calif., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
Symbol | Price | Vol. |
---|---|---|
AAPYKurv Yield Premium Strategy Apple AAPL ETF | $ 27.098 (0.00%) | 0 |
AAPXT Rex 2X Long Apple Daily Target ETF | $ 32.68 (0.00%) | 0 |
AAPRInnovator Equity Defined Protection ETF 2 Yr to April 2026 | $ 26.2001 (0.00%) | 0 |
AAAUGoldman Sachs Physical Gold ETF Shares | $ 26.31 (0.00%) | 0 |
AAAAlternative Access First Priority CLO Bond ETF | $ 25.085 (0.00%) | 0 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.